If we do this in an orderly way—and I hope in a non-political way—we might be of service to the people of this country.

I have had passed out copies of the agenda and, with your permission, I would like to start with the drug situation in connection with safety aspects and then go on to the pesticides and contamination of food, followed by the price discussion at the end. In this way we will be able to proceed in an orderly way.

The first section is the drug safety section which, I think, should be broken down into subsections, as discussed by the subcommittee. The first section would deal with the law and practices relating to the control of the introduction, marketing and use of drugs in Canada and this, no doubt should be broken down into a number of sections:

1. (*a*) The control of the introduction, marketing and use of drugs under the Food and Drugs Act and the regulations; (*b*) preclinical testing of drugs with reference to an evaluation of the safety of new drugs by means of tests on animals; (*c*) existing practices in respect of the testing of drugs in humans for the purpose of assessing safety and effectiveness; (*d*) a general appraisal of the present day practices in respect of the preclinical and clinical testing of drugs for marketing, and (*e*) existing practices in respect of the marketing of drugs.

2. Report by the chairman of the special committee of the Royal College of Physicians and Surgeons, under the direction of Dr. Brien. As indicated before, this report will be tabled in the house today by the Minister of National Health and Welfare and,

3. Report on existing legislation in various countries pertaining to the testing and distribution of drugs.

I would like to go into detail in the drug section point by point.

2. (*a*) It is my feeling that the Minister of National Health and Welfare Honourable J. Waldo Monteith, should make a statement pertaining to the terms of reference and give an explanation of the government's policy in this regard.

2. (*b*) The director of the food and drug directorate should explain the particular sections of the Food and Drugs Act and regulations which provide him with the authority to control the introduction of drugs into Canada.

He should explain the administrative procedures which are followed within the directorate to have a new drug released to the public for clinical and general use.

The director should explain the limitations in the existing act and regulations in respect of the control of both new and old drugs, which he feels are lacking.

Differences in the regulations in the United States and Canada in the handling of new drugs should be explained; for example, prescription drugs, research, preclinical requirements, effectiveness data and advertising.

The director should explain any difficulty pertaining to personnel make-up and so on, and perhaps mention any recruiting and understaffing problems.

2. (*c*) Pharmaceutical manufacturers should be asked to present the committee with a report on existing practices in respect of the preclinical testing of drugs. They should be asked to outline the type of preclinical testing which is carried out on various classes of drugs before the drugs go into clinical trials and give an evaluation of the effectiveness of present testing procedures in the prevention of serious side effects in humans during clinical trials, and later when the drug is released for general use.